Comparison · NCT02152995-deaths
Cohort A (Iodine I-124 PET/CT, Trametinib, Iodine I-131) vs Cohort B (Iodine I-124 PET/CT, Trametinib, Iodine I-131): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Download JSON
Cite this record
ConductScience Library. Cohort A (Iodine I-124 PET/CT, Trametinib, Iodine I-131) vs Cohort B (Iodine I-124 PET/CT, Trametinib, Iodine I-131): deaths from any cause. Trial comparisons, record NCT02152995-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02152995-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.24 | 0.115 | 0.434 | wilson | |
| Risk in group 2 | 0.111 | 0.0199 | 0.435 | wilson | |
| Risk difference, group 1 minus group 2 | 0.129 | -0.218 | 0.344 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.16 | 0.3 | 15.6 | log | |
| Odds ratio, group 1 over group 2 | 2.53 | 0.26 | 24.5 | log | |
| Number needed to harm, for one more death from any cause on Cohort A (Iodine I-124 PET/CT, Trametinib, Iodine I-131) than on Cohort B (Iodine I-124 PET/CT, Trametinib, Iodine I-131) | 7.76 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cohort A (Iodine I-124 PET/CT, Trametinib, Iodine I-131) | Patients with RAS gene mutations undergo iodine I-124 PET/CT on day 5 of week 1. Beginning day 6, patients receive trametinib PO daily for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo second iodine I-124 PET/CT on week 5. If I-124 PET/CT shows enough iodine absorption, patients may receive iodine I-131 PO and continue receiving trametinib for another 2 days. If I-124 shows that the thyroid is not absorbing iodine, patients have the option to be assigned to Cohort C.~Computed Tomography: Undergo iodine I-124 PET/CT~Iodine I 124: Undergo iodine I-124 PET/CT~Iodine I-131: Given PO~Laboratory Biomarker Analysis: Correlative studies~Pharmacodynamic Study: Correlative studies~Positron Emission Tomography: Undergo iodine I-124 PET/CT~Trametinib: Given PO | 6 | 25 | EG000 |
| Group 2 | Cohort B (Iodine I-124 PET/CT, Trametinib, Iodine I-131) | Patients without BRAF/RAS gene mutations undergo iodine I-124 PET/CT on day 5 of week 1. Beginning day 6, patients receive trametinib PO daily for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo second iodine I-124 PET/CT on week 5. If I-124 PET/CT shows enough iodine absorption, patients may receive iodine I-131 PO and continue receiving trametinib for another 2 days. If I-124 shows that the thyroid is not absorbing iodine, patients have the option to be assigned to Cohort C.~Computed Tomography: Undergo iodine I-124 PET/CT~Iodine I 124: Undergo iodine I-124 PET/CT~Iodine I-131: Given PO~Laboratory Biomarker Analysis: Correlative studies~Pharmacodynamic Study: Correlative studies~Positron Emission Tomography: Undergo iodine I-124 PET/CT~Trametinib: Given PO | 1 | 9 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Up to 1 year
Source ClinicalTrials.gov
Trial
- Title
- Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
- NCT number
- NCT02152995
- Phases
- PHASE2
- Conditions
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
- Interventions
- Computed Tomography, Iodine I 124, Iodine I-131, Laboratory Biomarker Analysis, Pharmacodynamic Study, Positron Emission Tomography, Trametinib
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2022-12-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02152995?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02152995-deaths